ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014
Activation of the trace amine-associated receptor 1 prevents relapse to cocaine seeking.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 86 citations in OpenAlex.
- Preclinical development of [European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.Biomedicines · 2023Review
- Natural Sympathomimetic Drugs: From Pharmacology to Toxicology.Biomolecules · 2022Review
- Selective TAAR1 agonists induce conditioned taste aversion.Psychopharmacology · 2022Article
- Improved cognitive performance in trace amine-associated receptor 5 (TAAR5) knock-out mice.Scientific reports · 2022Article
- TAAR1 regulates drug-induced reinstatement of cocaine-seeking via negatively modulating CaMKIIα activity in the NAc.Molecular psychiatry · 2022Article
- Activation of trace amine-associated receptor 1 attenuates nicotine withdrawal-related effects.Addiction biology · 2022Article
- Trace amine-associated receptor 1 and drug abuse.Advances in pharmacology (San Diego, Calif.) · 2022Article
- Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.International journal of molecular sciences · 2021Review
- Potential of Ligands for Trace Amine-Associated Receptor 1 (TAAR1) in the Management of Substance Use Disorders.CNS drugs · 2021Review
- Activation of trace amine-associated receptor 1 selectively attenuates the reinforcing effects of morphine.British journal of pharmacology · 2021Article
- Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.Pharmacology & therapeutics · 2020Review
- TAAR1 agonists attenuate extended-access cocaine self-administration and yohimbine-induced reinstatement of cocaine-seeking.British journal of pharmacology · 2020Article
- Effects of a trace amine-associated receptor 1 agonist RO 5263397 on ethanol-induced behavioral sensitization.Behavioural brain research · 2020Article
- TAAR1 and Psychostimulant Addiction.Cellular and molecular neurobiology · 2020Review
- TAAR Agonists.Cellular and molecular neurobiology · 2020Review
- Role of trace amine-associated receptor 1 in nicotine's behavioral and neurochemical effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- Deletion of Trace Amine-Associated Receptor 1 Attenuates Behavioral Responses to Caffeine.Frontiers in pharmacology · 2018Article
- Trace Amine Associated Receptor 1 (TAAR1) Modulation of Food Reward.Frontiers in pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The trace amine-associated receptor 1 (TAAR1) has emerged as a promising target for medication development in addiction because of its ability to regulate dopamine (DA) transmission. We tested in rats the efficacy of RO5203648 and RO5256390, partial and full TAAR1 agonists, respectively, in models of cocaine relapse. Using a model of context-induced relapse, both RO5203648 and RO5256390 dose-dependently suppressed cocaine seeking after a 2-week period of withdrawal from chronic cocaine self-administration. In a model of extinction-reinstatement, RO5203648 completely inhibited cocaine-primed reinstatement of cocaine seeking. At doses that effectively suppressed cocaine seeking neither RO5203648 nor RO5256390 altered responding maintained by a natural reward. Moreover, fast scan cyclic voltammetry data showed that RO5203648 prevented cocaine-induced DA overflow in the nucleus accumbens without altering DA half-life, suggesting that the partial TAAR1 agonist attenuated cocaine-stimulated DA overflow by mechanisms other than direct interference with DA uptake. Collectively, these data provide strong evidence in support of TAAR1 as a neuropharmacological target for the treatment of cocaine addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.